Pfizer Hasn't Proved Rare-Disease Drug Works, FDA Staff Says

Law360, New York (May 22, 2012, 1:40 PM EDT) -- Staff at the U.S. Food and Drug Administration on Tuesday said Pfizer Inc. has failed to prove the effectiveness of nerve disorder treatment Vyndaqel and recommended against approving the drug, potentially hampering the firm’s foray into the rare-disease market.

The agency’s feedback came in advance of a Thursday advisory committee meeting where a panel of outside experts will vote on whether the medicine should be cleared for sale.

Dr. Devanand Jillapalli, who analyzed clinical trial results submitted by Pfizer, concluded that there is “inadequate evidence of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.